Should mismatch repair status be determined in all stage II and III colon cancer patients?

References

• Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Popat S , HubnerR, HoulstonRS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3), 609–618 (2005).
   PubMed Web of Science ®Google Scholar
• Zaanan A , MeunierK, SangarF, FlejouJF, PrazF. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol. (Dordr.)34(3), 155–176 (2011).
   PubMed Web of Science ®Google Scholar
• Jass JR , DoKA, SimmsLAet al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut42(5), 673–679 (1998).
   PubMed Web of Science ®Google Scholar
• Leach FS , NicolaidesNC, PapadopoulosNet al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell75(6), 1215–1225 (1993).
   PubMed Web of Science ®Google Scholar
• Peltomaki P , AaltonenLA, SistonenPet al. Genetic mapping of a locus predisposing to human colorectal cancer. Science260(5109), 810–812 (1993).
   PubMed Web of Science ®Google Scholar
• Aaltonen LA , PeltomakiP, LeachFSet al. Clues to the pathogenesis of familial colorectal cancer. Science260(5109), 812–816 (1993).
   PubMed Web of Science ®Google Scholar
• Herman JG , UmarA, PolyakKet al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA95(12), 6870–6875 (1998).
   PubMed Web of Science ®Google Scholar
• Hampel H , FrankelWL, MartinEet al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med.352(18), 1851–1860 (2005).
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ , SiegmundKD, CampanMet al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet.38(7), 787–793 (2006).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network . Comprehensive molecular characterization of human colon and rectal cancer. Nature487(7407), 330–337 (2012).
   PubMed Web of Science ®Google Scholar
• Toyota M , AhujaN, Ohe-ToyotaM, HermanJG, BaylinSB, IssaJP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA96(15), 8681–8686 (1999).
   PubMed Web of Science ®Google Scholar
• Domingo E , LaihoP, OllikainenMet al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet.41(9), 664–668 (2004).
   PubMed Web of Science ®Google Scholar
• Boland CR , ThibodeauSN, HamiltonSRet al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res.58(22), 5248–5257 (1998).
   PubMed Web of Science ®Google Scholar
• Umar A , BolandCR, TerdimanJPet al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst.96(4), 261–268 (2004).
   PubMed Web of Science ®Google Scholar
• Lindor NM , BurgartLJ, LeontovichOet al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol.20(4), 1043–1048 (2002).
   PubMed Web of Science ®Google Scholar
• Roth AD , DelorenziM, TejparSet al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J. Natl Cancer Inst.104(21), 1635–1646 (2012).
   PubMedGoogle Scholar
• Hutchins G , SouthwardK, HandleyKet al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol.29(10), 1261–1270 (2011).
   PubMed Web of Science ®Google Scholar
• Gavin PG , ColangeloLH, FumagalliDet al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin. Cancer Res.18(23), 6531–6541 (2012).
   PubMed Web of Science ®Google Scholar
• O'connell MJ , LaveryI, YothersGet al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol.28(25), 3937–3944 (2010).
   PubMed Web of Science ®Google Scholar
• Salazar R , RoepmanP, CapellaGet al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol.29(1), 17–24 (2011).
   PubMed Web of Science ®Google Scholar
• Gray RG , QuirkeP, HandleyKet al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol.29(35), 4611–4619 (2011).
   PubMed Web of Science ®Google Scholar
• Parc Y , GueroultS, MourraNet al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut53(3), 371–375 (2004).
   PubMed Web of Science ®Google Scholar
• Elsaleh H , JosephD, GrieuF, ZepsN, SpryN, IacopettaB. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet355(9217), 1745–1750 (2000).
   PubMed Web of Science ®Google Scholar
• Hemminki A , MecklinJP, JarvinenH, AaltonenLA, JoensuuH. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology119(4), 921–928 (2000).
   PubMed Web of Science ®Google Scholar
• Westra JL , SchaapveldM, HollemaHet al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol.23(24), 5635–5643 (2005).
   PubMed Web of Science ®Google Scholar
• Carethers JM , SmithEJ, BehlingCAet al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology126(2), 394–401 (2004).
   PubMed Web of Science ®Google Scholar
• de Vos tot Nederveen Cappel WH , MeulenbeldHJ, KleibeukerJHet al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int. J. Cancer109(3), 468–471 (2004).
   PubMed Web of Science ®Google Scholar
• Benatti P , GafaR, BaranaDet al. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res.11(23), 8332–8340 (2005).
   PubMed Web of Science ®Google Scholar
• Jover R , ZapaterP, CastellsAet al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut55(6), 848–855 (2006).
   PubMed Web of Science ®Google Scholar
• Lanza G , GafaR, SantiniA, MaestriI, GuerzoniL, CavazziniL. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J. Clin. Oncol.24(15), 2359–2367 (2006).
   PubMed Web of Science ®Google Scholar
• Kim GP , ColangeloLH, WieandHSet al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol.25(7), 767–772 (2007).
   PubMed Web of Science ®Google Scholar
• Lamberti C , LundinS, BogdanowMet al. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int. J. Colorectal Dis.22(2), 145–152 (2007).
   PubMed Web of Science ®Google Scholar
• Ribic CM , SargentDJ, MooreMJet al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med.349(3), 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , MarsoniS, MongesGet al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol.28(20), 3219–3226 (2010).
   PubMed Web of Science ®Google Scholar
• Des Guetz G , SchischmanoffO, NicolasP, PerretGY, MorereJF, UzzanB. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer45(10), 1890–1896 (2009).
   PubMed Web of Science ®Google Scholar
• Jover R , NguyenTP, Perez-CarbonellLet al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology140(4), 1174–1181 (2011).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA , FosterNR, ThibodeauSNet al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl Cancer Inst.103(11), 863–875 (2011).
   PubMedGoogle Scholar
• Andre T , BoniC, Mounedji-BoudiafLet al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Kuebler JP , WieandHS, O'connellMJet al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol.25(16), 2198–2204 (2007).
   PubMed Web of Science ®Google Scholar
• Haller DG , TaberneroJ, MarounJet al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol.29(11), 1465–1471 (2011).
   PubMed Web of Science ®Google Scholar
• Tournigand C , AndreT, BonnetainFet al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J. Clin. Oncol.30(27), 3353–3360 (2012).
   PubMed Web of Science ®Google Scholar
• Kim ST , LeeJ, ParkSHet al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother. Pharmacol.66(4), 659–667 (2010).
   PubMed Web of Science ®Google Scholar
• Des Guetz G , LecailleC, MarianiPet al. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res.30(10), 4297–4301 (2010).
   PubMed Web of Science ®Google Scholar
• Zaanan A , Cuilliere-DartiguesP, GuillouxAet al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol.21(4), 772–780 (2010).
   PubMed Web of Science ®Google Scholar
• Zaanan A , FlejouJF, EmileJFet al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin. Cancer Res.17(23), 7470–7478 (2011).
   PubMed Web of Science ®Google Scholar
• Zaanan A , BonnetainF, SinicropeFA, Laurent-PuigP, TaiebJ. Colon cancer mutation: prognosis/prediction – letter. Clin. Cancer Res.19(5), 1301 (2013).
   PubMed Web of Science ®Google Scholar
• Flejou J-F , AndréT, ChibaudelBet al. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J. Clin. Oncol.31(Suppl.), Abstract 3524 (2013).
   Google Scholar
• Saltz LB , NiedzwieckiD, HollisDet al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol.25(23), 3456–3461 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , LabiancaR, BodokyGet al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol.27(19), 3117–3125 (2009).
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM , NiedzwieckiD, ComptonCCet al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol.27(11), 1814–1821 (2009).
   PubMed Web of Science ®Google Scholar
• Tejpar S , BosmanF, DelorenziMet al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J. Clin. Oncol.28(3 Suppl.), S15 (2009) (Abstract 4001).
   PubMedGoogle Scholar
• Sinicrope FA , MahoneyMR, SmyrkTCet al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J. Clin. Oncol.31(29), 3664–3672 (2013).
   PubMed Web of Science ®Google Scholar
• Pogue-Geile K , YothersG, TaniyamaYet al. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J. Natl Cancer Inst.105(13), 989–992 (2013).
   PubMedGoogle Scholar